Teva Pharmaceutical Industries Limited TEVA

Teva Pharmaceutical Industries Ltd es una empresa farmacéutica con sede en Israel. La Compañía opera a través de tres segmentos: América del Norte, Europa y Mercados Internacionales. Cada segmento comercial gestiona todo el portafolio de productos en su región, incluyendo genéricos, especialidades y productos de venta libre (OTC). Además de estos tres segmentos, la Compañía tiene otras actividades, principalmente la venta de ingredientes farmacéuticos activos (API) a terceros, ciertos servicios de fabricación por contrato y una plataforma de licencias que ofrece un portafolio de productos a otras compañías farmacéuticas a través de su afiliada Medis.

• Zacks Investment Research 30 sept

  Here's Why You Should Add URGN Stock to Your Portfolio Now

  UroGen Pharma is transitioning from development-stage to commercial-growth biotech, driven by strong Zusduri uptake (73% sequential revenue growth to $50.4M in Q2 2026) and stable Jelmyto sales ($22M in Q2). The company's pipeline includes promising candidates like UGN-103 (94.5% response rate with NDA submitted) and UGN-104, with potential to expand beyond urothelial cancers through a strategic collaboration with IntraGel.

  

• The Motley Fool 29 sept

  Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

  Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.

  

• GlobeNewswire Inc. 23 sept

  Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

  Teva Pharmaceutical Industries announced it will release its Q3 2026 financial results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. The company is executing its Pivot to Growth strategy focused on expanding its innovative and biosimilar medicines pipeline while maintaining its generics business.

  

• GlobeNewswire Inc. 23 sept

  Teva Releases Q3 2026 Aide Memoire

  Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire document to assist investors ahead of third quarter 2026 results, scheduled for release on November 3, 2026, followed by a conference call at 8:00 a.m. ET. The company is transforming into a leading innovative biopharmaceutical company supported by its generics business.

  

• GlobeNewswire Inc. 18 sept

  New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

  Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.